Stock ELVN ENLIVEN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Enliven Therapeutics, Inc.

Equities

ELVN

US29337E1029

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-31 EDT 		5-day change 1st Jan Change
22.57 USD +0.13% Intraday chart for Enliven Therapeutics, Inc. -5.72% +63.08%
05-20 Enliven Therapeutics Insider Sold Shares Worth $22,877,262, According to a Recent SEC Filing MT
05-14 Enliven Therapeutics Q1 Loss Narrows MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Enliven Therapeutics to Present at Two Upcoming Investor Conferences
Enliven Therapeutics Insider Sold Shares Worth $22,877,262, According to a Recent SEC Filing
Enliven Therapeutics Q1 Loss Narrows
Enliven Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
Enliven Therapeutics, Inc. Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
Enliven Therapeutics, Inc. Appoints Lori Kunkel to Board of Directors
Mizuho Securities Initiates Enliven Therapeutics With Buy Rating, Price Target is $34
Enliven Therapeutics, Inc. announced that it has received $90.000014 million in funding
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024
North American Morning Briefing : Investors -2-
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates
Enliven Therapeutics, Inc. announced that it expects to receive $90.000014 million in funding
Enliven Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
Enliven Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Enliven Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
Enliven Therapeutics, Inc.(NasdaqGS:ELVN) added to NASDAQ Biotechnology Index
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ELVN Stock
  4. News Enliven Therapeutics, Inc.
  5. Other languages